Cargando…
Targeted therapy for HER2 positive breast cancer
INTRODUCTION: Breast cancer is the second most common cause of death for women behind lung cancer and the most common cause of cancer deaths for women aged 45–55 years old (CDC.gov 2012). Although there continue to be enormously large numbers of disease incidence, deaths have been declining due to t...
Autores principales: | Incorvati, Jason A, Shah, Shilpan, Mu, Ying, Lu, Janice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703272/ https://www.ncbi.nlm.nih.gov/pubmed/23731980 http://dx.doi.org/10.1186/1756-8722-6-38 |
Ejemplares similares
-
Emerging Targeted Therapies for HER2-Positive Breast Cancer
por: Mercogliano, María Florencia, et al.
Publicado: (2023) -
Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
por: Yoshikawa, Ayumu, et al.
Publicado: (2022) -
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
por: Hackshaw, Michelle D., et al.
Publicado: (2020) -
Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer
por: Guan, Jingyuan, et al.
Publicado: (2021) -
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
por: Yang, Xiaojing, et al.
Publicado: (2023)